menu

CME: Precision Management in Non-Small Cell Lung Cancer: Addressing ALK+ Tumors

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Precision Management in Non-Small Cell Lung Cancer: Addressing ALK+ Tumors

Program Information
Recommended
Precision Management in Non-Small Cell Lung Cancer: Addressing ALK+ Tumors
RestartResume
Just how safe and effective is the use of ALK+ inhibitors for treating non-small cell lung cancer? Here’s what the latest clinical trials have found.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    ALK+ lung cancer occurs in about 5-7% of patients with non-small cell lung cancer, of which half of these patients develop brain metastases. That’s why more and more clinical trials are focusing on emerging treatment options, like ALK+ inhibitors.

    This activity will discuss what exactly these inhibitors are and their place in non-small cell lung cancer treatment paradigms.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Jennifer Logan Ackil, MSN, ANP-BC
    Oncology Nurse Practitioner
    Thoracic Oncology
    Massachusetts General Hospital
    Boston, MA

    No relationship reported.

    Faculty: 
    Alice T. Shaw, MD, PhD
    Director of Thoracic Oncology
    Massachusetts General Hospital
    Professor of Medicine
    Harvard Medical School
    Boston, MA

    Consulting Fees: Ariad, Bayer, Blueprint Medicines, Chugai, Daiichi-sankyo, EMD Serono, Genentech, Ignyta, KSQ Therapeutics, Loxo Oncology, Natera, Novartis, Pfizer, Roche, Taiho Pharmaceutical, Takeda, TP Therapeutics
    Honoraria: Foundation Medicine, Genentech, Guardant, Novartis, Pfizer, Roche                                              Grants/Research: Ariad, Genentech, Ignyta, Novartis, Pfizer, Roche, TP Therapeutics

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Lawrence Sherman, FACEHP, CHCP has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.

     

  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with non-small cell lung cancer. After participating in this educational activity, participants should be better able to:

    • Formulate strategies to incorporate the latest recommendations for molecular profiling of NSCLC as means to overcome current adoption barriers.
    • Identify the respective roles of oncology team members with regard to diagnosing and managing patients with ALK+ NSCLC.
    • Evaluate evidence from clinical trials on the effectiveness and safety of approved and emerging ALK TKIs, and assess their place in current treatment paradigms.
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists and other members of the interprofessional team who are involved in the management of patients with non-small cell lung cancer.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech and Takeda Oncology.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 8/25/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.